American Century Companies Inc. Has $1.63 Million Position in Artivion, Inc. $AORT

American Century Companies Inc. lifted its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 14.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 66,406 shares of the company's stock after acquiring an additional 8,635 shares during the quarter. American Century Companies Inc. owned about 0.16% of Artivion worth $1,632,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AORT. Legacy Advisors LLC acquired a new position in shares of Artivion in the 1st quarter valued at about $28,000. MCF Advisors LLC grew its holdings in Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion in the 4th quarter worth $64,000. Raymond James Financial Inc. bought a new position in Artivion in the 4th quarter worth $275,000. Finally, Natixis Advisors LLC lifted its stake in shares of Artivion by 16.4% in the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after buying an additional 1,777 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Artivion

In related news, SVP Marshall S. Stanton sold 26,132 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $28.44, for a total transaction of $743,194.08. Following the transaction, the senior vice president directly owned 79,200 shares of the company's stock, valued at approximately $2,252,448. This trade represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James P. Mackin sold 12,500 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the transaction, the chief executive officer directly owned 852,783 shares in the company, valued at approximately $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 115,990 shares of company stock valued at $4,435,823 in the last three months. 8.10% of the stock is owned by insiders.

Artivion Stock Performance

Shares of AORT traded down $0.61 during trading hours on Friday, hitting $43.42. The company had a trading volume of 371,694 shares, compared to its average volume of 545,017. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -103.39 and a beta of 1.69. The business has a fifty day moving average of $36.34 and a 200-day moving average of $29.79. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm's revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AORT has been the topic of a number of recent analyst reports. JMP Securities boosted their price target on shares of Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research report on Friday, August 8th. Stifel Nicolaus boosted their price target on shares of Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Needham & Company LLC boosted their price target on shares of Artivion from $45.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. Finally, Canaccord Genuity Group upped their target price on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $40.63.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.